Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 3/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.39 |
| ▸ | MET | P08581 | 5/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.36 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24569404 | 0.89 | EGLN2 (0.41) | EGLN2CYP17A1METAAK1MAPK14 | |
| SCHEMBL24167374 | 0.89 | EGLN2 (0.40) | EGLN2CYP17A1MAPK14HDAC3HDAC8 | |
| SCHEMBL22122738 | 0.81 | EGLN2 (0.53) | EGLN2CYP17A1MAPK14HDAC3HDAC8 | |
| SCHEMBL1137136 | 0.77 | CYP17A1 (0.47) | CYP17A1METAAK1MAPK14SYK | |
| SCHEMBL24167687 | 0.74 | EGLN2 (0.44) | EGLN2CYP17A1MAPK14HDAC3HDAC8 | |
| SCHEMBL24168107 | 0.73 | EGLN2 (0.43) | EGLN2CYP17A1MAPK14HDAC3HDAC8 | |
| SCHEMBL24167370 | 0.72 | TGFBR1 (0.37) | EGLN2MET | |
| SCHEMBL24167636 | 0.71 | EGLN2 (0.42) | EGLN2CYP17A1METMAPK14HDAC3 | |
| SCHEMBL22821822 | 0.71 | EGLN2 (0.48) | EGLN2CYP17A1MAPK14HDAC3HDAC8 | |
| SCHEMBL38661795 | 0.70 | EGLN2 (0.45) | EGLN2CYP17A1AAK1SYKMAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265098-A1 | ALKYNE QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN INC. | 2023-08-24 | — | — | US | disclosed |
| WO-2022006386-A1 | ALKYNE QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN THERAPEUTICS, INC. (US) | 2022-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265098-A1 | ALKYNE QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ERBB2, ERBB3, CHEK2 | EGLN2 2945/4885CYP17A1 3210/4885MET 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.